Ixazomib citrate is under clinical development by Millennium Pharmaceuticals and currently in Phase II for Secondary Progressive Multiple Sclerosis (SPMS). According to GlobalData, Phase II drugs for Secondary Progressive Multiple Sclerosis (SPMS) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ixazomib citrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ixazomib citrate overview
Ixazomib citrate (MLN9708 / Ninlaro) acts as an anti neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. It is under development of cold agglutinin disease (cAIHA) and relapsed or refractory light chain amyloidosis, immune thrombocytopenia (ITP), interstitial lung disease, relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma, kidney cancer(second-line therapy), advanced solid tumors including urothelial cell cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma and glioblastoma multiforme, hematological malignancies including relapsed/refractory acute myeloid leukemia (AML), acute and chronic myelogenous leukemia, relapsing remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis, acute and chronic lymphocytic leukemia, low-grade, intermediate Hodgkin and non-Hodgkin lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, plasmablastic lymphoma, angioimmunoblastic T-cell lymphoma (AITL). It was also under development for newly diagnosed multiple myeloma, Waldenstrom macroglobulinemia, head and neck cancer squamous cell carcinoma, soft tissue sarcoma and prostate cancer, lupus nephritis, systemic lupus erythematosus, refractory autoimmune cytopenia including warm autoimmune hemolytic anemia (wAIHA), relapsed/refractory primary amyloidosis, metastatic renal cell carcinoma, metastatic triple negative breast cancer, high risk myelodysplastic syndrome, relapsed /refractory cutaneous T-cell lymphoma, sezary syndrome, mycosis fungoides, anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphomas (PTCL), intravenous pediatric patients with relapsed/refractory acute lymphoblastic leukemia, relapsed/refractory lymphoblastic lymphoma and graft versus host disease.
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals (Takeda Oncology), a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that offers cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. Takeda Oncology is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Ixazomib citrate’s drug-specific PTSR and LoA scores, buy the report here.